Results 171 to 180 of about 202,778 (267)

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Data Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells: Targeting RAS/RAF Signalling. [PDF]

Oncol Res
Anggriawan IMB, Jørgensen HG.
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state. [PDF]

J Transl Med
Zhang L, Xiang G, Zhu P, Yu S, Jiang F, Wang S, Wang J, Dai Y, Wang S, Tan Y, Liu H, Liu F.   +11 more
europepmc   +1 more source

RAS Family Gene Mutation [PDF]

, 2020
openaire   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer. [PDF]

Nat Commun
Wagner V, Bousset L, Ascensão-Ferreira M, Sun B, Barragan Avila JE, Kaizeler A, Martins-Silva R, Rahbari M, Fernández-Vaquero M, Haston S, Tinti M, Pombo J, Khadayate S, Roth S, Schürch CM, Martínez-Barbera JP, Bahat A, Wee KB, Morton JP, Malek N, Innes AJ, Vernia S, Barbosa-Morais NL, Gallage S, Heikenwalder M, Gil J.   +25 more
europepmc   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model. [PDF]

Cureus
Findling E, Bissoondial T, Narayan P.
europepmc   +1 more source

Metabolic Flux Analysis Reveals Cell Line‐Specific Rewiring in CHO Cells Following TCA Cycle Intermediate Feeding for Bioprocess pH Control

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Chinese hamster ovary (CHO) cells are the leading host for recombinant therapeutic protein production in the biopharma industry. In this study, we investigated how feeding acidic forms of tricarboxylic acid (TCA) cycle intermediates—malic acid, succinic acid, and α‐ketoglutaric acid—affects cell culture performance and metabolism in two ...
Sarah A. Sacco, Kevin J. Ruiz‐Márquez, Rachel Moen, Irina Trenary, Xiaolin Zhang, Xiaowen Wang, Malik Padellan, Henry Lin, Jamey D. Young   +8 more
wiley   +1 more source